Who are mammalian Omega 3 Fatty acids's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epanova, TRIGEL, Palmitoleic Acid + Infliximab, Eicosapentaenoic acid ethyl ester, fenofibrate/omega, Product 3 - Standard Fish Oil Triglyceride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mammalian-omega-3-fatty-acids.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

mammalian Omega 3 Fatty acids — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

mammalian Omega 3 Fatty acids (mammalian Omega 3 Fatty acids) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fatty acid. Area: Cardiovascular.

phase 3 Fatty acid Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

mammalian Omega 3 Fatty acids (mammalian Omega 3 Fatty acids) — McGill University Health Centre/Research Institute of the McGill University Health Centre. Mammalian Omega 3 Fatty acids work by reducing inflammation and improving cardiovascular health through their effects on the body's fatty acid metabolism.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
mammalian Omega 3 Fatty acids TARGET	mammalian Omega 3 Fatty acids	McGill University Health Centre/Research Institute of the McGill University Health Centre	phase 3	Fatty acid
Epanova	OMEGA-3-CARBOXYLIC ACIDS	AstraZeneca	marketed	Omega-3 Fatty Acid		2014-01-01
TRIGEL	TRIGEL	LobSor Pharmaceuticals AB	marketed	Fatty acid synthase inhibitor	Fatty acid synthase
Palmitoleic Acid + Infliximab	Palmitoleic Acid + Infliximab	Chinese Medical Association	marketed	TNF-α inhibitor + fatty acid combination	TNF-α receptor (via infliximab); GPR120 and other metabolic sensors (via palmitoleic acid)
Eicosapentaenoic acid ethyl ester	Eicosapentaenoic acid ethyl ester	Yamaguchi University Hospital	marketed	Omega-3 fatty acid / Triglyceride-lowering agent
fenofibrate/omega	fenofibrate/omega	Gachon University Gil Medical Center	marketed	Fibrate + omega-3 fatty acid combination	PPARα (peroxisome proliferator-activated receptor alpha)
Product 3 - Standard Fish Oil Triglyceride	Product 3 - Standard Fish Oil Triglyceride	RDC Clinical Pty Ltd	marketed	Omega-3 fatty acid supplement

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fatty acid class)

Brigham and Women's Hospital · 1 drug in this class
Federal University of São Paulo · 1 drug in this class
McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 drug in this class
Università degli Studi di Brescia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). mammalian Omega 3 Fatty acids — Competitive Intelligence Brief. https://druglandscape.com/ci/mammalian-omega-3-fatty-acids. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab